SCHEMBL10201212

SCHEMBL10201212

Nc1cccnc1NC[C@H](NBC=O)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.34
HSD17B10 Q99714 2/20 0.33
SHMT2 P34897 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
TSHR P16473 1/20 0.32
KMT2A Q03164 3/20 0.31
MEN1 O00255 2/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NAPRT Q6XQN6 1/20 0.31
BACE1 P56817 1/20 0.30
DHODH Q02127 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201215 0.87 FDPS (0.35) FDPSHSD17B10KDM4EALDH1A1HPGD
SCHEMBL12450921 0.80 HDAC1 (0.38) NPC1RAB9AHDAC1
SCHEMBL13140027 0.79 FDPS (0.36) FDPSHSD17B10SHMT2KDM4EALDH1A1
SCHEMBL644995 0.73 PPARA (0.44)
SCHEMBL1669341 0.70 SHMT2 (0.45) HSD17B10SHMT2KDM4EALDH1A1HPGD
SCHEMBL13140024 0.68 KMT2A (0.38) FDPSHSD17B10KDM4EALDH1A1HPGD
SCHEMBL3871792 0.68 CYP2D6 (0.59) HSD17B10KDM4EHPGDTSHRNPC1
SCHEMBL24398169 0.68 ACP1 (0.42) FDPSHSD17B10KDM4EALDH1A1HPGD
SCHEMBL5958469 0.68 CA12 (0.40) FDPSHSD17B10SHMT2KDM4EALDH1A1
SCHEMBL9691928 0.67 ALDH1A1 (0.45) HSD17B10SHMT2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B FDPS 1431/4885HSD17B10 1135/4885SHMT2 3909/4885
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B FDPS 1431/4885HSD17B10 1135/4885SHMT2 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.